Theravance Biopharma, Inc. [TBPH] - Theravance Biopharma / Zymeworks merger
Theravance Biopharma, Inc. will merge with Zymeworks Inc. through its wholly owned subsidiary, Zymeworks Merger Sub 1, with the company becoming a wholly owned subsidiary of Zymeworks as part of the transaction.
Why this matters
Theravance Biopharma, Inc., a pharmaceutical company based in California, focuses on developing and commercializing respiratory and other specialty medicines. The company has announced a merger with Zymeworks Inc. through its wholly owned subsidiary, Zymeworks Merger Sub 1, resulting in Theravance becoming a wholly owned subsidiary of Zymeworks. This strategic move follows a review of strategic alternatives and is formalized under a merger agreement that includes a termination fee of $32,515,000 under specified circumstances.